For this a separate cohort was used consisting of cognitively healthy control cases (n = 8) without any Aβ or tau pathology, 2) AD cases with severe Aβ plaque pathology but no vascular deposits (no CAA) (n = 8) and 3) AD cases with severe CAA type-1 pathology (n = 6). This evidence concerns the gene MAPT and Alzheimer disease.